1. Holford NH. Antagonism of some spasmogens of the rat seminal vesicle. Br J Pharmacol.
1972;46(3):522P.
2. Davidson JK, Morley P, Hurley GD, Holford NG. Adrenal venography and ultrasound in
the investigation of the adrenal gland: an analysis of 58 cases. Br J Radiol.
1975;48(570):435-50.
3. Holford N, Sheiner LB. The digoxin concentration: before and after the fact. Am Heart J.
1977;94(4):529-30.
4. Holford NH, Vozeh S, Coates P, Powell JR, Thiercelin JF, Upton R. More on heparin lock.
N Engl J Med. 1977;296(22):1300-1.
5. Guentert TW, Holford NH, Coates PE, Upton RA, Riegelman S. Quinidine
pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. J
Pharmacokinet Biopharm. 1979;7(4):315-30.
6. Guentert TW, Upton RA, Holford NH, Riegelman S. Divergence in pharmacokinetic
parameters of quinidine obtained by specific and nonspecific assay methods. J
Pharmacokinet Biopharm. 1979;7(3):303-11.
7. Guentert TW, Upton RA, Holford NH, Bostrom A, Riegelman S. Gastrointestinal
absorption of quinidine from some solutions and commercial tablets. J Pharmacokinet
Biopharm. 1980;8(3):243-55.
8. Holford NH. Quinidine-digoxin interaction. Ann Intern Med. 1980;93(4):638-9.
9. Holford NH. Internal medicine-epitomes of progress: digoxin, quinidine and sudden death.
West J Med. 1980;133(3):233-4.
10. Holford NH. The quinidine-digoxin interaction. N Engl J Med. 1980;302(15):864.
11. Scheinman MM, Remedios P, Cheitlin MD, Peters RW, Holford N, Desai J, et al. Effects
of antiarrhythmic drugs on atrioventricular conduction in patients with acute myocardial
infarction. Circulation. 1980;62(1):20-8.
12. Upton RA, Buskin JN, Williams RL, Holford NH, Riegelman S. Negligible excretion of
unchanged ketoprofen, naproxen, and probenecid in urine. J Pharm Sci. 1980;69(11):1254-7.
13. Whiting B, Holford NH, Sheiner LB. Quantitative analysis of the disopyramide
concentration-effect relationship. Br J Clin Pharmacol. 1980;9(1):67-75.
14. Frey FJ, Amend WJ, Lozada F, Frey BM, Holford NH, Benet LZ. Pharmacokinetics of
prednisolone and endogenous hydrocortisone levels in cushingoid and non-cushingoid
patients. Eur J Clin Pharmacol. 1981;21(3):235-42.
15. Holford NH, Coates PE, Guentert TW, Riegelman S, Sheiner LB. The effect of quinidine
and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect
relationships. Br J Clin Pharmacol. 1981;11(2):187-95.
16. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of
pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981;6(6):429-53.
17. Holford NH, Sheiner LB. Pharmacokinetic and pharmacodynamic modeling in vivo. Crit
Rev Bioeng. 1981;5(4):273-322.
18. Bikle DD, Peck CC, Holford NH, Zolock DT, Morrissey RL. Pharmacokinetics and
pharmacodynamics of 1,25-dihydroxyvitamin D3 in the chick. Endocrinology.
1982;111(3):939-46.
19. Frey BM, Frey FJ, Holford NH, Lozada F, Benet LZ. Prednisolone pharmacodynamics
assessed by inhibition of the mixed lymphocyte reaction. Transplantation. 1982;33(6):578-84.
20. Gambertoglio JG, Frey FJ, Holford NH, Birnbaum JL, Lizak PS, Vincenti F, et al.
Prednisone and prednisolone bioavailability in renal transplant patients. Kidney Int.
1982;21(4):621-6.
21. Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther.
1982;16(2):143-66.
22. Rakhit A, Kunitani M, Holford NH, Riegelman S. Improved liquid-chromatographic assay
of quinidine and its metabolites in biological fluids. Clin Chem. 1982;28(7):1505-9.
23. Silber B, Holford NH, Riegelman S. Stereoselective disposition and glucuronidation of
propranolol in humans. J Pharm Sci. 1982;71(6):699-704.
24. Williams RL, Blume CD, Lin ET, Holford NH, Benet LZ. Relative bioavailability of
chlorthalidone in humans: adverse influence of polyethylene glycol. J Pharm Sci.
1982;71(5):533-5.
25. Silber BM, Holford NH, Riegelman S. Dose-dependent elimination of propranolol and its
major metabolites in humans. J Pharm Sci. 1983;72(7):725-32.
26. Tozer TN, Gambertoglio JG, Furst DE, Avery DS, Holford NH. Volume shifts and protein
binding estimates using equilibrium dialysis: application to prednisolone binding in humans. J
Pharm Sci. 1983;72(12):1442-6. 10
27. Gambertoglio JG, Holford NH, Kapusnik JE, Nishikawa R, Saltiel M, Stanik-Lizak P, et al.
Disposition of total and unbound prednisolone in renal transplant patients receiving
anticonvulsants. Kidney Int. 1984;25(1):119-23.
28. Rakhit A, Guentert TW, Holford NH, Verhoeven J, Riegelman S. Pharmacokinetics and
pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs. Eur J
Drug Metab Pharmacokinet. 1984;9(4):315-24.
29. Rakhit A, Holford NH, Effeney DJ, Riegelman S. Induction of quinidine metabolism and
plasma protein binding by phenobarbital in dogs. J Pharmacokinet Biopharm.
1984;12(5):495-515.
30. Rakhit A, Holford NH, Guentert TW, Maloney K, Riegelman S. Pharmacokinetics of
quinidine and three of its metabolites in man. J Pharmacokinet Biopharm. 1984;12(1):1-21.
31. Rosenbaum JS, Holford NH, Richards ML, Aman RA, Sadee W. Discrimination of three
types of opioid binding sites in rat brain in vivo. Mol Pharmacol. 1984;25(2):242-8.
32. Rosenbaum JS, Holford NH, Sadee W. Opiate receptor binding-effect relationship:
sufentanil and etorphine produce analgesia at the mu-site with low fractional receptor
occupancy. Brain Res. 1984;291(2):317-24.
33. Thibonnier M, Holford NH, Upton RA, Blume CD, Williams RL. Pharmacokinetic-
pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma
samples in man. J Pharmacokinet Biopharm. 1984;12(6):559-73.
34. Rosenbaum JS, Holford NH, Sadee W. In vivo receptor binding of opioid drugs at the mu
site. J Pharmacol Exp Ther. 1985;233(3):735-40.
35. Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin.
Understanding the dose-effect relationship. Clin Pharmacokinet. 1986;11(6):483-504.
36. Mahood CB, Rothwell RP, Holford N. Slow-release theophylline (THEO-24). N Z Med J.
1986;99(794):21.
37. Mahood CB, Rothwell RP, Holford NH. Slow release theophylline (Theo-24). N Z Med J.
1986;99(797):165.
38. Webster DR, Boston GD, Holford NH, Paton DM. Relationship of metabolism of 2'-, 3'-
and 5'-adenine nucleotides to presynaptic inhibition of transmitter release in rat vas deferens.
Naunyn Schmiedebergs Arch Pharmacol. 1986;333(2):163-7.
39. Faull RL, Villiger JW, Holford NH. Benzodiazepine receptors in the human cerebellar
cortex: a quantitative autoradiographic and pharmacological study demonstrating the
predominance of type I receptors. Brain Res. 1987;411(2):379-85.
40. Holford NH. Clinical pharmacokinetics of ethanol. Clin Pharmacokinet. 1987;13(5):273-92.
41. Holford NH, Clements P, Collier P, Orie NG, van Bork LE, Jonkman JH.
Pharmacokinetics and pharmacodynamics of thiazinamium in asthmatic patients. Eur J Clin
Pharmacol. 1987;33(3):237-42.
42. Milne RJ, Gamble GD, Holford NH. Behavioural tolerance to morphine analgesia is
supraspinally mediated: a quantitative analysis of dose-response relationships. Brain Res.
1989;491(2):316-27.
43. Holford NH. Concepts and usefulness of pharmacokinetic-pharmacodynamic modelling.
Fundam Clin Pharmacol. 1990;4 Suppl 2:93s-101s.
44. Holford NH. Relevance of pharmacodynamic principles in therapeutics. Ann Acad Med
Singapore. 1991;20(1):26-30.
45. Ware GJ, Holford NH, Davison JG. Unit dose dispensing. N Z Med J. 1991;104(908):125.
46. Ware GJ, Holford NH, Davison JG, Harris RG. Unit dose calendar packaging and elderly
patient compliance. N Z Med J. 1991;104(924):495-7.
47. Holford NH. beta-blockers vs calcium channel blockers vs ACE inhibitors.
Pharmacoeconomics. 1992;1(6):460-1.
48. Holford NH, Ambros RJ, Stoeckel K. Models for describing absorption rate and estimating
extent of bioavailability: application to cefetamet pivoxil. J Pharmacokinet Biopharm.
1992;20(5):421-42.
49. Holford NH, Peace KE. Results and validation of a population pharmacodynamic model
for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci U S A.
1992;89(23):11471-5. 11
50. Holford NH, Peace KE. Methodologic aspects of a population pharmacodynamic model
for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci U S A.
1992;89(23):11466-70.
51. Holford N, Black P, Couch R, Kennedy J, Briant R. Theophylline target concentration in
severe airways obstruction - 10 or 20 mg/L? A randomised concentration-controlled trial. Clin
Pharmacokinet. 1993;25(6):495-505.
52. Holford N, Hashimoto Y, Sheiner LB. Time and theophylline concentration help explain
the recovery of peak flow following acute airways obstruction. Population analysis of a
randomised concentration controlled trial. Clin Pharmacokinet. 1993;25(6):506-15.
53. Guentert TW, Holford NH, Pfefen JP, Dingemanse J. Mixed linear and non-linear
disposition of lazabemide, a reversible and selective inhibitor of monoamine oxidase B. Br J
Clin Pharmacol. 1994;37(6):545-51.
54. Holford NH, Guentert TW, Dingemanse J, Banken L. Monoamine oxidase-A:
pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. Br J Clin
Pharmacol. 1994;37(5):433-9.
55. Holford NH, Guentert TW, Dingemanse J, Kettler R. Pharmacodynamics of lazabemide, a
reversible and selective inhibitor of monoamine oxidase B. Br J Clin Pharmacol.
1994;37(6):553-7.
56. Holford NH, Peace K. The effect of tacrine and lecithin in Alzheimer's disease. A
population pharmacodynamic analysis of five clinical trials. Eur J Clin Pharmacol.
1994;47(1):17-23.
57. Anderson BJ, Woolard GA, Holford NH. Pharmacokinetics of rectal paracetamol after
major surgery in children. Paediatr Anaesth. 1995;5(4):237-42.
58. Guentert TW, Banken L, Hilton S, Holford NH. Moclobemide: relationships between dose,
drug concentration in plasma, and occurrence of adverse events. J Clin Psychopharmacol.
1995;15(4 Suppl 2):84S-94S.
59. Holford NH. The target concentration approach to clinical drug development. Clin
Pharmacokinet. 1995;29(5):287-91.
60. Holford NH. Input from the deep south compartment. A personal viewpoint. Clin
Pharmacokinet. 1995;29(3):139-41.
61. Holford NH, Williams PE, Muirhead GJ, Mitchell A, York A. Population
pharmacodynamics of romazarit. Br J Clin Pharmacol. 1995;39(3):313-20.
62. Veszelovsky E, Holford NH, Thomsen LL, Knowles RG, Baguley BC. Plasma nitrate
clearance in mice: modeling of the systemic production of nitrate following the induction of
nitric oxide synthesis. Cancer Chemother Pharmacol. 1995;36(2):155-9.
63. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30(5):329-
32.
64. Nutt JG, Holford NH. The response to levodopa in Parkinson's disease: imposing
pharmacological law and order. Ann Neurol. 1996;39(5):561-73.
65. Anderson BJ, Holford NH. Rectal paracetamol dosing regimens: determination by
computer simulation. Paediatr Anaesth. 1997;7(6):451-5.
66. Anderson BJ, Holford NH, Woollard GA. Aspects of theophylline clearance in children.
Anaesth Intensive Care. 1997;25(5):497-501.
67. Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of
analgesia in paediatric patients. Clin Pharmacokinet. 1997;33(5):313-27.
68. Holford NH. Complex PK/PD models--an alcoholic experience. Int J Clin Pharmacol Ther.
1997;35(10):465-8.
69. Pruijn FB, van Daalen M, Holford NH, Wilson WR. Mechanisms of enhancement of the
antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-
acetic acid. Cancer Chemother Pharmacol. 1997;39(6):541-6.
70. Reid AW, Anderson BJ, Futter ME, Holford NH. Relationship of muscle strength to
potassium concentration in a hypokalaemic infant. Anaesth Intensive Care. 1997;25(5):525-7.
71. Anderson BJ, Holford NH. Rectal acetaminophen pharmacokinetics. Anesthesiology.
1998;88(4):1131-3.
72. Anderson BJ, Holford NH, Woollard GA, Chan PL. Paracetamol plasma and
cerebrospinal fluid pharmacokinetics in children. Br J Clin Pharmacol. 1998;46(3):237-43. 12
73. Anderson BJ, Monteleone J, Holford NH. Variability of concentrations after rectal
paracetamol. Paediatr Anaesth. 1998;8(3):274.
74. Reith D, Monteleone JP, Whyte IM, Ebelling W, Holford NH, Carter GL. Features and
toxicokinetics of clozapine in overdose. Ther Drug Monit. 1998;20(1):92-7.
75. Anderson BJ, Gunn TR, Holford NH, Johnson R. Caffeine overdose in a premature infant:
clinical course and pharmacokinetics. Anaesth Intensive Care. 1999;27(3):307-11.
76. Anderson BJ, Holford NH, Armishaw JC, Aicken R. Predicting concentrations in children
presenting with acetaminophen overdose. J Pediatr. 1999;135(3):290-5.
77. Anderson BJ, Holford NH, Woollard GA, Kanagasundaram S, Mahadevan M.
Perioperative pharmacodynamics of acetaminophen analgesia in children. Anesthesiology.
1999;90(2):411-21.
78. du Preez MJ, Botha JH, McFadyen ML, Holford NH. The pharmacokinetics of
theophylline in premature neonates during the first few days after birth. Ther Drug Monit.
1999;21(6):598-603.
79. Holford NH. Target concentration intervention: beyond Y2K. Br J Clin Pharmacol.
1999;48(1):9-13.
80. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the
validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed.
1999;59(1):19-29.
81. Schuitmaker M, Anderson BJ, Holford NH, Woollard GA. Pharmacokinetics of
paracetamol in adults after cardiac surgery. Anaesth Intensive Care. 1999;27(6):615-22.
82. Anderson BJ, Holford NH. Reply. J Pediatr. 2000;137(6):892.
83. Anderson BJ, Pearce S, McGann JE, Newson AJ, Holford NH. Investigations using
logistic regression models on the effect of the LMA on morphine induced vomiting after
tonsillectomy. Paediatr Anaesth. 2000;10(6):633-8.
84. Anderson BJ, Ralph CJ, Stewart AW, Barber C, Holford NH. The dose-effect relationship
for morphine and vomiting after day-stay tonsillectomy in children. Anaesth Intensive Care.
2000;28(2):155-60.
85. Anderson BJ, Woollard GA, Holford NH. A model for size and age changes in the
pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol.
2000;50(2):125-34.
86. Holford NH, Kimko HC, Monteleone JP, Peck CC. Simulation of clinical trials. Annu Rev
Pharmacol Toxicol. 2000;40:209-34.
87. Kimko HC, Reele SS, Holford NH, Peck CC. Prediction of the outcome of a phase 3
clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a
population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther.
2000;68(5):568-77.
88. Anderson BJ, Woollard GA, Holford NH. Acetaminophen analgesia in children: placebo
effect and pain resolution after tonsillectomy. Eur J Clin Pharmacol. 2001;57(8):559-69.
89. Chan PL, Holford NH. Drug treatment effects on disease progression. Annu Rev
Pharmacol Toxicol. 2001;41:625-59.
90. Gobburu JV, Holford NH. Vz, the terminal phase volume: time for its terminal phase? J
Biopharm Stat. 2001;11(4):373-5.
91. Grange S, Holford NH, Guentert TW. A pharmacokinetic model to predict the PK
interaction of L-dopa and benserazide in rats. Pharm Res. 2001;18(8):1174-84.
92. Holford NH. Target concentration intervention: beyond Y2K. Br J Clin Pharmacol.
2001;52 Suppl 1:55S-9S.
93. Michelsen LG, Holford NH, Lu W, Hoke JF, Hug CC, Bailey JM. The pharmacokinetics of
remifentanil in patients undergoing coronary artery bypass grafting with cardiopulmonary
bypass. Anesth Analg. 2001;93(5):1100-5.
94. Anderson BJ, van Lingen RA, Hansen TG, Lin YC, Holford NH. Acetaminophen
developmental pharmacokinetics in premature neonates and infants: a pooled population
analysis. Anesthesiology. 2002;96(6):1336-45.
95. Hauser RA, Holford NH. Quantitative description of loss of clinical benefit following
withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov
Disord. 2002;17(5):961-8. 13
96. Mould DR, Holford NH, Schellens JH, Beijnen JH, Hutson PR, Rosing H, et al. Population
pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin
Pharmacol Ther. 2002;71(5):334-48.
97. Sheiner LB, Holford NH. Determination of maximum effect. Clin Pharmacol Ther.
2002;71(4):304; author reply -5.
98. Whiting B, Holford NH, Begg EJ. Clinical pharmacology: principles and practice of drug
therapy in medical education. Br J Clin Pharmacol. 2002;54(1):1-2.
99. Frey N, Laveille C, Paraire M, Francillard M, Holford NH, Jochemsen R. Population
PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day
modified release (MR) formulation. Br J Clin Pharmacol. 2003;55(2):147-57.
100. van der Marel CD, Anderson BJ, van Lingen RA, Holford NH, Pluim MA,
Jansman FG, et al. Paracetamol and metabolite pharmacokinetics in infants. Eur J Clin
Pharmacol. 2003;59(3):243-51.
101. Anderson BJ, Holford NH. No urine, no urinary clearance. Eur J Clin Pharmacol.
2004;60(4):297.
102. Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH. Developmental
pharmacokinetics of morphine and its metabolites in neonates, infants and young
children. Br J Anaesth. 2004;92(2):208-17.
103. Chan PL, Nutt JG, Holford NH. Modeling the short- and long-duration responses
to exogenous levodopa and to endogenous levodopa production in Parkinson's disease.
J Pharmacokinet Pharmacodyn. 2004;31(3):243-68.
104. Matthews I, Kirkpatrick C, Holford N. Quantitative justification for target
concentration intervention--parameter variability and predictive performance using
population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol.
2004;58(1):8-19.
105. Chan PL, Nutt JG, Holford NH. Pharmacokinetic and pharmacodynamic changes
during the first four years of levodopa treatment in Parkinson's disease. J Pharmacokinet
Pharmacodyn. 2005;32(3-4):459-84.
106. Chan PL, Nutt JG, Holford NH. Importance of within subject variation in levodopa
pharmacokinetics: a 4 year cohort study in Parkinson's disease. J Pharmacokinet
Pharmacodyn. 2005;32(3-4):307-31.
107. Duffull SB, Kirkpatrick CM, Green B, Holford NH. Analysis of population
pharmacokinetic data using NONMEM and WinBUGS. J Biopharm Stat. 2005;15(1):53-
73.
108. Allegaert K, Anderson BJ, Cossey V, Holford NH. Limited predictability of
amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol.
2006;61(1):39-48.
109. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of
children: general principles. Eur J Pediatr. 2006;165(11):741-6.
110. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of
children: modelling covariate effects. Eur J Pediatr. 2006;165(12):819-29.
111. DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, et al.
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients
with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety,
pharmacokinetics, and pharmacodynamics. Blood. 2006;108(12):3674-81.
112. Holford NH, Chan PL, Nutt JG, Kieburtz K, Shoulson I. Disease progression and
pharmacodynamics in Parkinson disease - evidence for functional protection with
levodopa and other treatments. J Pharmacokinet Pharmacodyn. 2006;33(3):281-311.
113. Lockwood P, Ewy W, Hermann D, Holford N. Application of clinical trial
simulation to compare proof-of-concept study designs for drugs with a slow onset of
effect; an example in Alzheimer's disease. Pharm Res. 2006;23(9):2050-9.
114. Tannenbaum SJ, Holford NH, Lee H, Peck CC, Mould DR. Simulation of
correlated continuous and categorical variables using a single multivariate distribution. J
Pharmacokinet Pharmacodyn. 2006;33(6):773-94. 14
115. Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NH.
Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance.
Br J Clin Pharmacol. 2007;63(1):75-84.
116. Chan PL, Nutt JG, Holford NH. Levodopa slows progression of Parkinson's
disease: external validation by clinical trial simulation. Pharm Res. 2007;24(4):791-802.
117. Fang L, Holford NH, Hinkle G, Cao X, Xiao JJ, Bloomston M, et al. Population
pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine
antibody CC49 in colorectal cancer patients. J Clin Pharmacol. 2007;47(2):227-37.
118. Herd DW, Anderson BJ, Holford NH. Modeling the norketamine metabolite in
children and the implications for analgesia. Paediatr Anaesth. 2007;17(9):831-40.
119. Holford N, Karlsson MO. Time for quantitative clinical pharmacology: a proposal
for a pharmacometrics curriculum. Clin Pharmacol Ther. 2007;82(1):103-5.
120. Overgaard RV, Holford N, Rytved KA, Madsen H. PKPD model of interleukin-21
effects on thermoregulation in monkeys--application and evaluation of stochastic
differential equations. Pharm Res. 2007;24(2):298-309.
121. Tham LS, Holford NH, Hor SY, Tan T, Wang L, Lim RC, et al. Lack of association
of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha,
and constitutive androstane receptor with docetaxel pharmacokinetics. Clin Cancer Res.
2007;13(23):7126-32.
122. Anand KJ, Anderson BJ, Holford NH, Hall RW, Young T, Shephard B, et al.
Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates:
secondary results from the NEOPAIN trial. Br J Anaesth. 2008;101(5):680-9.
123. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in
pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303-32.
124. Herd DW, Anderson BJ, Keene NA, Holford NH. Investigating the
pharmacodynamics of ketamine in children. Paediatr Anaesth. 2008;18(1):36-42.
125. Holford N, Nutt JG. Disease progression, drug action and Parkinson's disease:
why time cannot be ignored. Eur J Clin Pharmacol. 2008;64(2):207-16.
126. Iida S, Kinoshita H, Holford NH. Population pharmacokinetic and
pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart
failure. Br J Clin Pharmacol. 2008;66(3):352-65.
127. Tham LS, Wang L, Soo RA, Lee SC, Lee HS, Yong WP, et al. A
pharmacodynamic model for the time course of tumor shrinkage by gemcitabine +
carboplatin in non-small cell lung cancer patients. Clin Cancer Res. 2008;14(13):4213-8.
128. Tham LS, Wang LZ, Soo RA, Lee HS, Lee SC, Goh BC, et al. Does saturable
formation of gemcitabine triphosphate occur in patients? Cancer Chemother Pharmacol.
2008;63(1):55-64.
129. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation
to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25-36.
130. Ploeger BA, Holford NH. Washout and delayed start designs for identifying
disease modifying effects in slowly progressive diseases using disease progression
analysis. Pharm Stat. 2009;8(3):225-38.
131. Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, et al.
Human renal function maturation: a quantitative description using weight and
postmenstrual age. Pediatr Nephrol. 2009;24(1):67-76.
132. Anderson BJ, Holford NH. Leaving no stone unturned, or extracting blood from
stone? Paediatr Anaesth. 2010;20(1):1-6.
133. Forsyth R, Thuy V, Salorio C, Christensen J, Holford N. Review: efficient
rehabilitation trial designs using disease progress modeling: a pediatric traumatic brain
injury example. Neurorehabil Neural Repair. 2010;24(3):225-34.
134. Holford N. Dosing in children. Clin Pharmacol Ther. 2010;87(3):367-70.
135. Holford N, Ma SC, Ploeger BA. Clinical trial simulation: a review. Clin Pharmacol
Ther. 2010;88(2):166-82.
136. Nutt JG, Chung KA, Holford NH. Dyskinesia and the antiparkinsonian response
always temporally coincide: a retrospective study. Neurology. 2010;74(15):1191-7. 15
137. Potts AL, Anderson BJ, Holford NH, Vu TC, Warman GR. Dexmedetomidine
hemodynamics in children after cardiac surgery. Paediatr Anaesth. 2010;20(5):425-33.
138. Bulitta JB, Kinzig M, Jakob V, Holzgrabe U, Sörgel F, Holford NHG. Nonlinear
pharmacokinetics of piperacillin in healthy volunteers – implications for optimal dosage
regimens. British Journal of Clinical Pharmacology. 2010;70(5):682-93.
139. Cortinez LI, Anderson BJ, Penna A, Olivares L, Munoz HR, Holford NH, et al.
Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br
J Anaesth. 2010;105(4):448-56.
140. Holford N. Holford NHG and Sheiner LB "Understanding the Dose-Effect
Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models", Clin
Pharmacokin 6:429-453 (1981)-The Backstory. AAPS J. 2011;13(4):662-4
141. Anderson B, Holford N. Evaluation of a morphine maturation model for the
prediction of morphine clearance in children. Br J Clin Pharmacol. 2011;72(3):518-20
142. Chigutsa E, Visser ME, Swart EC, Denti P, Pushpakom S, Egan D, et al. The
SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated
with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother.
2011;55(9):4122-7
143. Holford NH, Nutt JG. Interpreting the results of Parkinson's disease clinical trials:
Time for a change. Mov Disord. 2011;26(4):569-77
144. Sumpter AL, Holford NHG. Predicting weight using postmenstrual age –
neonates to adults. Pediatric Anesthesia. 2011;21(3):309-15
145. Anderson BJ, Holford NHG. Tips and traps analyzing pediatric PK data. Pediatric
Anesthesia. 2011;21(3):222-37
146. Patel K, Choy SS, Hicks KO, Melink TJ, Holford NH, Wilson WR. A combined
pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and
mice predicts species differences in clearance and toxicity. Cancer Chemother Pharmacol.
2011;67(5):1145-55
147. Holford NHG, Ma SC, Ploeger BA. Response to validation and assessment of
predictive performance in simulation models of clinical trials. Clinical Pharmacology &
Therapeutics. 2011;89(4):488
148. Gengiah TN, Holford NH, Botha JH, Gray AL, Naidoo K, Abdool Karim SS. The
influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV
and tuberculosis. Eur J Clin Pharmacol 2012; 68: 689-95.
149. Holford NH, Ma SC, Anderson BJ. Prediction of morphine dose in humans.
Paediatr Anaesth 2012; 22: 209-22.
150. Vu TC, Nutt JG, Holford NHG. Disease progress and response to treatment as
predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.
Br J Clin Pharmacol 2012; 74: 284-95.
151. Vu TC, Nutt JG, Holford NHG. Progression of motor and nonmotor features of
Parkinson's disease and their response to treatment. Br J Clin Pharmacol 2012; 74: 267-83.
152. Holford N. Modeling helps in understanding antidepressants. Clin Pharmacol
Ther 2012; 92: 155-6.
153. Senn S, Holford N, Hockey H. The ghosts of departed quantities: approaches to
dealing with observations below the limit of quantitation. Stat Med 2012; 31(30): 4280-4295
154. Holford NHG, Buclin T. Safe and effective variability – A criterion for dose
individualization. Ther Drug Monit 2012; 34 (5), 565-568.
155. Zhao W, Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV, Holford N,
Kimura T, Lo YL, Peris J-E, Thomson A, van den Anker JN, Fakhoury M, Jacqz-Aigrain E.
External evaluation of population pharmacokinetic models of vancomycin in neonates: The
transferability of published models to different clinical settings. British Journal of Clinical
Pharmacology 2012; doi: 10.1111/j.1365-2125.2012.04406.x
156. Thai H-T, Mentre F, Holford NHG, Veyrat-Follet C, Comets E. A comparison of
bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models.
Pharmaceutical Statistics 2013;doi: 10.1002/pst.1561
157. Holford N. A Time to Event Tutorial for Pharmacometricians. CPT: pharmacomet
syst pharmacol. 2013;2:e43 doi: 10.1038/psp.2013.18
158. Holford N, Heo Y-A, Anderson B. A pharmacokinetic standard for babies and
adults. J Pharm Sci. 2013:DOI 10.1002/jps.23574 doi: 10.1002/jps.23574
159. Holford NHG. Disease progression and neuroscience. Journal of
Pharmacokinetics and Pharmacodynamics. 2013;40:369-76 doi: 10.1007/s10928-013-9316-2
160. Wright DF, Stamp LK, Merriman TR, Barclay ML, Duffull SB, Holford NH. The
population pharmacokinetics of allopurinol and oxypurinol in patients with gout. Eur J Clin
Pharmacol. 2013; doi: 10.1007/s00228-013-1478-8
161. Holford NHG. Clinical pharmacology = disease progression + drug action. British
Journal of Clinical Pharmacology. 2013; doi: 10.1111/bcp.12170
|
